Business
Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- - Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today reported fourth quarter and full year 2024 financial results. Prioritized resources on potentially disruptive autoimmune programs while enabling maturation of clinical data from oncology programs to further su
About this update from Cue Biopharma, Inc.
[{"type":"image","alt":"Cue Biopharma, Inc.","displaySize":"","headline":null,"caption":"Cue Biopharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":152,"url":"https://media.zenfs.com/en/globenewswire.com/4abc48ed7cfcf5ab851f707c4025a5e7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/OFA8Tw.y_lEOLBxRzL5SvA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4abc48ed7cfcf5ab851f707c4025a5e7","width":300,"height":152}},"lazy":false},{"type":"text","content":"BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- - Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today reported fourth quarter and full year 2024 financial results.","length":362,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Prioritized resources on potentially disruptive autoimmune programs while enabling maturation of clinical data from oncology programs to further support prospective strategic partnerships","length":187,"tagName":"p"}]},{"val":[{"type":"text","content":"Appointed key industry leaders to management team and board of directors","length":72,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Lucinda Warren, Chief Business OfficerIndustry veteran, with extensive experience and proven expertise in strategic transactions, portfolio optimization and alliance management","length":177,"tagName":"p"}]},{"val":[{"type":"text","content":"Daniel Baker, M.D., Interim Chief Development OfficerOver 20 years of drug development experience in the pharmaceutical industry","length":129,"tagName":"p"}]},{"val":[{"type":"text","content":"Pasha Sarraf, M.D., Ph.D., Member of Board of Directors Physician-scientist with extensive experience in the business of science and biotechnology","length":147,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":453,"olType":false}]},{"val":[{"type":"text","content":"Successfully regained worldwide development and commercialization rights for CUE-401, the Company’s lead autoimmune program with potential to transform treatment across a broad spectrum of autoimmune and inflammatory diseases","length":225,"tagName":"p"}]},{"val"...